Literature DB >> 7901028

Ontogenetic quinpirole treatment induces vertical jumping activity in rats.

R M Kostrzewa1, J Guo, F P Kostrzewa.   

Abstract

Repeated ontogenetic treatment with quinpirole produces enhanced quinpirole-induced yawning and antinociceptive actions in adult rats. We now report the occurrence of a bizarre jumping behavior in rats so treated. Rats were treated daily from birth with quinpirole HCl (3.0 mg/kg per day x 28 days i.p., salt form) or saline vehicle. After each daily injection, the rats were observed for at least 1 h. Starting on the 18th day after birth, quinpirole treatment was associated with the appearance of jumping behavior. On the 20th day after birth a dose-effect relationship was found for quinpirole HCl (0.10-3.0 mg/kg), with maximal jumping activity occurring between 30 and 150 min after the 3.0 mg/kg dose. On the 26th day after birth, both spiperone HCl (0.30 mg/kg i.p.) and SCH 23390 HCl (0.30 mg/kg i.p.) attenuated the quinpirole effect. At 34 days the jumping response was virtually absent. The age-related jumping behavior appears to be another manifestation of the abnormal responses mediated by supersensitized dopamine receptors in quinpirole-primed rats. Based on the ability of dopamine D1 and D2 receptor antagonists to attenuate this effect, quinpirole-induced jumping behavior may be a reflection of cooperativity of dopamine D1 and D2 receptor types.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901028     DOI: 10.1016/0014-2999(93)90992-q

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  Stereotypic progressions in psychotic behavior.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Rose Anna Kostrzewa; Florence P Kostrzewa; Ryszard Brus; Przemyslaw Nowak
Journal:  Neurotox Res       Date:  2010-04-22       Impact factor: 3.911

2.  Neonatal quinpirole treatment enhances locomotor activation and dopamine release in the nucleus accumbens core in response to amphetamine treatment in adulthood.

Authors:  Zackary A Cope; Kimberly N Huggins; A Brianna Sheppard; Daniel M Noel; David S Roane; Russell W Brown
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

3.  Prenatal amphetamine exposure effects on dopaminergic receptors and transporter in postnatal rats.

Authors:  Gonzalo Flores; María de Jesús Gómez-Villalobos; Leonardo Rodríguez-Sosa
Journal:  Neurochem Res       Date:  2011-05-25       Impact factor: 3.996

Review 4.  Dopamine D2 Receptor Supersensitivity as a Spectrum of Neurotoxicity and Status in Psychiatric Disorders.

Authors:  Richard M Kostrzewa; Karolina Wydra; Malgorzata Filip; Cynthia A Crawford; Sanders A McDougall; Russell W Brown; Dasiel O Borroto-Escuela; Kjell Fuxe; Raul R Gainetdinov
Journal:  J Pharmacol Exp Ther       Date:  2018-06-19       Impact factor: 4.030

5.  Neonatal 6-hydroxydopamine lesioning enhances quinpirole-induced vertical jumping in rats that were quinpirole primed during postnatal ontogeny.

Authors:  Richard M Kostrzewa; Florence P Kostrzewa
Journal:  Neurotox Res       Date:  2011-08-19       Impact factor: 3.911

6.  Dopamine D2 agonist priming in intact and dopamine-lesioned rats.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Przemyslaw Nowak; Rose A Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 7.  Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Russell W Brown; Przemyslaw Nowak; Ryszard Brus
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

8.  Dopamine receptor supersensitivity: an outcome and index of neurotoxicity.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats.

Authors:  Ryszard Brus; Richard M Kostrzewa; Przemysław Nowak; Ken W Perry; John P Kostrzewa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Perinatal Treatments with the Dopamine D₂-Receptor Agonist Quinpirole Produces Permanent D₂-Receptor Supersensitization: a Model of Schizophrenia.

Authors:  Richard M Kostrzewa; Przemysław Nowak; Ryszard Brus; Russell W Brown
Journal:  Neurochem Res       Date:  2015-11-07       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.